Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00420212
Status:
COMPLETED
Last Update Posted:
2015-01-26
First Post:
2007-01-08
Brief Title:
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
Sponsor:
Biogen
Organization:
Biogen
Study Overview
Official Title:
A Randomized Multicenter Double-Blind Placebo-Controlled Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis
Status:
COMPLETED
Status Verified Date:
2015-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DEFINE
Brief Summary:
To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period To determine if over time BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for the disease to get worse
The purpose of this study is also to determine the safety of BG00012 and how well it is tolerated Another goal is to see what effect BG00012 may have on tests and evaluations used to assess MS
The purpose of this study is also to determine the safety of BG00012 and how well it is tolerated Another goal is to see what effect BG00012 may have on tests and evaluations used to assess MS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None